Please login to the form below

Not currently logged in
Email:
Password:

INC Research expands infectious diseases team with appointment of Dr Frederick Young

He joins the CRO from ICON, where he served as vice president of strategic programmes

INC Research has appointed ICON's former vice president of strategic programmes Dr Frederick Young as vice president of infectious diseases.

The contract research organisation (CRO) says the addition of Dr Young will support its work in global vaccine development research as well as expanding its infectious diseases team.

"Antibiotics and other antimicrobials have played a critical role in the fight against infectious diseases, but further discovery and evaluation of new treatments is still needed," said Patricia Monteforte, executive vice president and general manager, general medicine, INC Research.

"We've become a leader in infectious diseases research by having a therapeutically-focused team with experience in all stages and disciplines associated with the development of anti-infectives. With the addition of Frederick, INC Research is positioned to expand this therapeutic unit even further with experienced resources to support and advance our customers' research and development."

Prior to his time with ICON, where he worked for nearly four years, Dr Young served at Novartis in a number of roles, including clinical research scientist, executive director, project leader and, most recently, global programme director.

25th April 2012

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Jet Off with Maloff Protect

Latest intelligence

“Fake News” and Credibility in Medical Publishing
Natalie Yeadon from Impetus Digital shares her thoughts on fighting fake news in Pharma and healthcare....
Delivering true value: what does it mean for KAM in cancer care?
Lisa Alderson, Business Development Director at Wilmington Healthcare, explores the challenges that pharma’s KAM teams face in engaging with the NHS and how they must evolve...
Pharma M&A
Pharma funding and M&A in 2020
Why pharma M&A has continually bucked the trend...

Infographics